HC Wainwright Reiterates "Buy" Rating for Kura Oncology (NASDAQ:KURA)

HC Wainwright reaffirmed their buy rating on shares of Kura Oncology (NASDAQ:KURA - Free Report) in a research report released on Wednesday morning,Benzinga reports. They currently have a $32.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Stifel Nicolaus cut shares of Kura Oncology from a "buy" rating to a "hold" rating and reduced their target price for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Wedbush reissued an "outperform" rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Monday, November 4th. Lifesci Capital raised shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, October 22nd. UBS Group started coverage on Kura Oncology in a research note on Thursday, October 24th. They issued a "buy" rating and a $27.00 price target for the company. Finally, JMP Securities restated a "market outperform" rating and set a $32.00 price objective on shares of Kura Oncology in a research note on Monday, August 12th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $28.83.

Kura Oncology Stock Down 5.5 %

NASDAQ:KURA traded down $1.03 during mid-day trading on Wednesday, hitting $17.54. 488,363 shares of the stock were exchanged, compared to its average volume of 893,343. The firm's 50-day simple moving average is $18.67 and its 200 day simple moving average is $19.99. Kura Oncology has a fifty-two week low of $8.80 and a fifty-two week high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Institutional Investors Weigh In On Kura Oncology

A number of large investors have recently modified their holdings of the business. Avoro Capital Advisors LLC increased its position in Kura Oncology by 29.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company's stock worth $82,120,000 after purchasing an additional 870,000 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Kura Oncology by 50.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company's stock worth $35,653,000 after buying an additional 577,732 shares in the last quarter. Affinity Asset Advisors LLC lifted its stake in shares of Kura Oncology by 281.4% in the 1st quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company's stock valued at $15,581,000 after acquiring an additional 538,957 shares during the last quarter. Sofinnova Investments Inc. lifted its stake in shares of Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company's stock valued at $16,992,000 after acquiring an additional 323,303 shares during the last quarter. Finally, Armistice Capital LLC boosted its holdings in shares of Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company's stock valued at $48,386,000 after acquiring an additional 302,000 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.